Crossmark

Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system

Published Online: 2026-02-28

Authors

Chen, Tingting

Liang, Min
License Information

Text and Data Mining valid from 2026-02-28

Accepted Manuscript valid from 2026-02-28
More Information

Article History

Received: 9 January 2025

Accepted: 4 February 2026

First Online: 28 February 2026

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that there are no conflicts of interest regarding this study.

Document is current